Top Markets
Coin of the day
EFFECTOR Therapeutics, Inc. EFFECTOR Therapeutics, Inc.

EFFECTOR Therapeutics, Inc.

EFTRW
Hisse Senetlerindeki Sıralama #42260
eFFECTOR Therapeutics, Inc. is a biopharmaceutical firm currently in the... eFFECTOR Therapeutics, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective translation regulator inhibitors aimed at combating cancer. Their primary investigational drug, Tomivosertib, is an orally administered small-molecule MNK inhibitor currently undergoing Phase 2b clinical trials. This candidate is being evaluated for its efficacy in patients suffering from metastatic non-small cell lung cancer. Additionally, the company is advancing zotatifin, another small molecule engineered to block eukaryotic initiation factor 4A (eIF4E). Zotatifin is presently in Phase 1/2 clinical studies for individuals with various solid tumors. Furthermore, it's being tested in a Phase 2a open-label expansion cohort, in conjunction with fulvestrant and abemaciclib, for patients afflicted with ER-positive breast cancer. eFFECTOR Therapeutics, Inc. also holds a research collaboration and licensing pact with Pfizer Inc., focused on co-developing eIF4E inhibitors. Established in 2012, the company maintains its corporate headquarters in Solana Beach, California.
Hisse Fiyatı
$0.0006
Son senkronizasyon: 2025-11-25
Piyasa Değeri
$2.82K
Değişim (1 gün)
59,900.00%
Değişim (1 yıl)
59,900.00%
Ülke
US
Ticaret EFFECTOR Therapeutics, Inc. (EFTRW)

Kategori

EFFECTOR Therapeutics, Inc. (EFTRW) için P/S oranı
2026 itibarıyla P/S oranı TTM: 0
EFFECTOR Therapeutics, Inc. şirketinin en son mali raporları ve hisse fiyatına göre, mevcut P/S oranı (TTM) 0'dir. 2026 yılının sonunda şirketin P/S oranı 0 idi.
EFFECTOR Therapeutics, Inc. için P/S oranı geçmişi 2026 - 2026 arası
Her yılın sonunda P/S oranı
Yıl P/S Oranı Değiştir
Sağlanan tarihler için yeterli veri yok.
Benzer şirketler veya rakipler için P/S oranı
Şirket P/S Oranı P/S Oranı Farkı Ülke
9.88 -
US
10.30 -
NL
- -
CH
4.98 -
BE
- -
KR